This Plain Language Summary of Publication article (PLSP) from Future Oncology investigated whether a combination therapy of encorafenib plus cetuximab with mFOLFOX6 could provide better outcomes than standard treatments for BRAF V600E-mutant metastatic colorectal cancer. This specific cancer mutation is particularly challenging to treat because patients often don’t respond well to conventional therapies and frequently experience disease progression.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial’ and was published in Nature Medicine.

Visit Nature using the link to read the original article.